The European Commission has proposed changing intellectual property rules to allow generic and biosimilar drug manufacturers to sell their products in markets outside the EU before the patents expire in
The European Commission has proposed changing intellectual property rules to allow generic and biosimilar drug manufacturers to sell their products in markets outside the EU before the patents expire in